Amendments to the Specification:

Please replace the paragraph beginning at page 20, line 3, with the following amended paragraph:

A preferred agent within the context of the present invention is an agent based upon the binding determinants of the monoclonal antibody S2C6 (Paulie et al., (1984) Cancer Immunol. Immunother. 17:165-179). S2C6 comprises the $V_\lambda$-amino-acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and the $V_\mu$-amino-acid sequences of SEQ ID NO:6 and SEQ ID NO:7 of WO 00/75348. While S2C6 has been shown to have an agonist activity on human peripheral B cells as demonstrated by its ability to stimulate primary B cell proliferation in a dose dependent manner (Paulie et al., (1989) J. Immunol. 142:590-595), agents based upon the antibody have been shown to have anti-neoplastic activity in vivo (International Publication No. WO 00/75348).